Page 42 - Read Online

Tokuyasu et al. J Cancer Metastasis Treat 2018;4:2 I http://dx.doi.org/10.20517/2394-4722.2017.52 Page 23 of 24

Bex A. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol 2015;67:100-10.
206. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards
of Reporting Trials Group. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised
trials. J Clin Epidemiol 2010;63:e1-37.
207. Simon R. Development and validation of biomarker classifiers for treatment selection. J Stat Plan Inference 2008;138:308-20.
208. Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G, De Marinis F. Predictive biomarkers of
immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Transl Lung Cancer Res 2017;6:373-86.
209. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK):
explanation and elaboration. PLoS Med 2012;9:e1001216.
210. Sekula P, Mallett S, Altman DG, Sauerbrei W. Did the reporting of prognostic studies of tumour markers improve since the
introduction of REMARK guideline? A comparison of reporting in published articles. PLoS One 2017;12:e0178531.
211. Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee
PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B. Systematic evaluation of immune regulation and modulation. J
Immunother Cancer 2017;5:21.
212. Haris M, Bagga P, Hariharan H, McGettigan-Croce B, Johnson LA, Reddy R. Molecular imaging biomarkers for cell-based
immunotherapies. J Transl Med 2017;15:140.
213. Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall
SC, Fong L, Nolan GP, Engleman EG. Systemic immunity is required for effective cancer immunotherapy. Cell 2017;168:487-502.
e15.
214. Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi
AP, Alvarado MD, Rosenblum MD, Daud AI. Partially exhausted tumor-infiltrating lymphocytes predict response to combination
immunotherapy. JCI Insight 2017;2:93433.
215. Kirsch I, Vignali M, Robins H. T-cell receptor profiling in cancer. Mol Oncol 2015;9:2063-70.
216. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko
+
S, Douek DC, Yang JC, Rosenberg SA. PD-1 identifies the patient-specific CD8 tumor-reactive repertoire infiltrating human tumors.
J Clin Invest 2014;124:2246-59.
217. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, Koya RC, Graeber
TG, Robins H, Ribas A. CTLA4 blockade broadens the peripheral t-cell receptor repertoire. Clin Cancer Res 2014;20:2424-32.
218. Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford CT, Asemissen AM, Thiele B,
Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M. T-cell diversification reflects antigen selection in the blood
of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. Int J Cancer 2017;140:2535-44.
219. Dziubianau M, Hecht J, Kuchenbecker L, Sattler A, Stervbo U, Rödelsperger C, Nickel P, Neumann AU, Robinson PN, Mundlos S,
Volk HD, Thiel A, Reinke P, Babel N. TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of
T cell-related pathology. Am J Transplant 2013;13:2842-54.
220. Rosati E, Dowds CM, Liaskou E, Henriksen EKK, Karlsen TH, Franke A. Overview of methodologies for T-cell receptor repertoire
analysis. BMC Biotechnol 2017;17:61.
221. Madi A, Poran A, Shifrut E, Reich-Zeliger S, Greenstein E, Zaretsky I, Arnon T, Laethem FV, Singer A, Lu J, Sun PD, Cohen IR,
Friedman N. T cell receptor repertoires of mice and humans are clustered in similarity networks around conserved public CDR3
sequences. Elife 2017;6:e22057.
222. Emerson RO, DeWitt WS, Vignali M, Gravley J, Hu JK, Osborne EJ, Desmarais C, Klinger M, Carlson CS, Hansen JA, Rieder M,
Robins HS. Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell
repertoire. Nat Genet 2017;49:659-65.
223. Garner JP, Gaskill BN, Weber EM, Ahloy-Dallaire J, Pritchett-Corning KR. Introducing Therioepistemology: the study of how
knowledge is gained from animal research. Lab Anim (NY) 2017;46:103-13.
224. Klevorn LE, Teague RM. Adapting cancer immunotherapy models for the real world. Trends Immunol 2016;37:354-63.
225. Davis MM. Immunology taught by humans. Sci Transl Med 2012;4:117fs2.
226. Steinman RM. Research on human subjects in the JEM. J Exp Med 2005;201:1349-50.
227. Hurez V, Padrón ÁS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol
2017;187:53-63.
228. Institute of Medicine (US). Sharing clinical research data: workshop summary. Washington (DC): National Academies Press (US);
2013.
229. Klinke DJ 2nd. A multiscale systems perspective on cancer, immunotherapy, and interleukin-12. Mol Cancer 2010;9:242.
230. Palsson S, Hickling TP, Bradshaw-Pierce EL, Zager M, Jooss K, O’Brien PJ, Spilker ME, Palsson BO, Vicini P. The development of
a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.
BMC Syst Biol 2013;7:95.
231. Narang V, Decraene J, Wong SY, Aiswarya BS, Wasem AR, Leong SR, Gouaillard A. Systems immunology: a survey of modeling
formalisms, applications and simulation tools. Immunol Res 2012;53:251-65.
232. Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol
2009;16:7-15.
233. Romiti A, Falcone R, Roberto M, Marchetti P. Current achievements and future perspectives of metronomic chemotherapy. Invest New